查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2044508

龐貝氏症：新型態療法、未滿足的需求與TPP洞察報告，2026年

Pompe Disease - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國龐貝氏症市場預計將從 2025 年的 7,400 萬美元成長到 2035 年的 1.85 億美元，這表明在預測期內市場將大幅擴張。
  • 推動市場成長的因素如下：
  • 提高晚髮型龐貝氏症患者的診斷和治療率。
  • 先進且昂貴的酵素替代療法的應用日益普及
  • 提高患者存活率和長期疾病管理
  • 未來的市場擴張將主要取決於能夠改善長期功能結果、減輕治療負擔和解決進行性肌肉萎縮問題的創新。

龐貝氏症的新治療方法及對TPP的深入了解

Thelansis 的「龐貝病：新興治療方法、未滿足的需求和目標產品概況 (TPP) 洞察報告 - 2026」對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

龐貝氏症概述

龐貝氏症是一種罕見的、進行性的體染色體隱性遺傳溶小體貯積症，由GAA基因編碼的酸性α-葡萄Glucosidase（GAA）缺乏所引起。這會導致溶酶體內肝醣病理性積累，主要涉及骨骼肌、心肌和平滑肌，造成不可逆的細胞損傷和器官功能障礙。疾病的嚴重程度與殘餘GAA酶活性呈負相關，其臨床表現多種多樣，從典型的嬰兒型龐貝病（出生後數月內出現肥厚型心肌病、嚴重肌張力低下和呼吸衰竭，如不治療迅速致命）到晚髮型龐貝病（兒童或成年期出現進行性進行性肌病和呼吸衰竭，但心臟功能通常保持正常）。診斷主要採用乾血斑GAA酶活性檢測作為初步篩檢手段，並透過GAA基因定序和肌肉切片檢查證實溶酶體內肝醣累積來確診。酵素替代療法（Glucosidaseα）已成為治療的基礎，但Glucosidaseα聯合藥理學Chaperone米格魯司他則代表著一項重大進展，與標準酶替代療法相比，該聯合療法在糖原清除率和臨床功能改善方面均表現出更優的療效。透過肺功能檢查、夜間氧飽和度監測以及包括非侵入性通氣在內的呼吸支持來監測呼吸功能是治療的關鍵支柱。物理治療和多學科復健可最佳化功能能力。早期啟動治療，特別是新生兒篩檢計畫的引入，已顯著改善了預後。以患者為中心的照護、遺傳諮詢和心理社會支持對於疾病的長期管理至關重要。

主要亮點

  • 德國的龐貝氏症患者人數預計將從 2025 年的 1401 人增加到 2035 年的 1510 人，這反映了診斷技術的進步和患者生存率的逐步提高。
  • 德國各地對罕見疾病的認知不斷提高，基因檢測的準確性不斷提高，罕見疾病篩檢計畫的擴大，使得罕見疾病的診斷越來越早。
  • 目前，酵素替代療法 (ERT) 是主要的治療方法，但人們對療效和組織滲透性較好的下一代治療方法越來越感興趣。
  • 目前仍缺乏能夠解決長期肌肉萎縮、呼吸功能下降以及對現有 ERT 療法反應差異等問題的持續治療方案。
  • 基因療法和增強型 GAA 替代療法等目前正在研發的治療方法有望徹底改變未來的治療模式。

一項針對醫生和關鍵意見領袖（KOL）的調查得出的結論：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 大公司
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Genzyme, a Sanofi Company
  • Shionogi
  • AskBio Inc.
  • Amicus Therapeutics
  • GeneCradle Inc.
  • Astellas Gene Therapies

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興治療方法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Pompe Disease Emerging Therapy and TPP Insights

Thelansis's "Pompe Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Pompe Disease Overview

Pompe disease is a rare, progressive autosomal recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA) - encoded by the GAA gene - resulting in pathological intralysosomal glycogen accumulation predominantly within skeletal, cardiac, and smooth muscle, causing irreversible cellular damage and organ dysfunction. Disease severity correlates inversely with residual GAA enzyme activity, producing a clinical spectrum ranging from classic infantile-onset Pompe disease - presenting within months of birth with hypertrophic cardiomyopathy, profound hypotonia, respiratory failure, and rapidly fatal course without treatment - to late-onset disease manifesting with progressive proximal myopathy, respiratory insufficiency, and preserved cardiac function across childhood or adulthood. Diagnosis integrates dried blood spot GAA enzyme activity assay as the primary screening tool, confirmed by GAA gene sequencing and muscle biopsy demonstrating lysosomal glycogen accumulation. Enzyme replacement therapy - alglucosidase alfa - established the therapeutic foundation, while cipaglucosidase alfa combined with the pharmacological chaperone miglustat represents a significant advancement, demonstrating superior glycogen clearance and clinically meaningful functional improvements over standard ERT. Respiratory surveillance with pulmonary function testing, nocturnal oximetry, and ventilatory support - including non-invasive ventilation - are critical management pillars. Physiotherapy and multidisciplinary rehabilitation optimise functional capacity. Prognosis has improved substantially with early treatment initiation, particularly through newborn screening programmes; patient-centred care, genetic counselling, and psychosocial support are integral to long-term disease management.

Key Highlights

  • In Germany, Pompe Disease prevalent cases are projected to increase from 1,401 patients in 2025 to 1,510 patients in 2035, reflecting gradual improvement in diagnosis and patient survival.
  • Increasing awareness, improved genetic testing, and expansion of rare disease screening programs are supporting earlier diagnosis across Germany.
  • Current treatment landscape is primarily dominated by enzyme replacement therapies (ERTs), with growing focus on next-generation therapies offering improved efficacy and tissue penetration.
  • Persistent unmet need exists for durable treatment options capable of addressing long-term muscle degeneration, respiratory decline, and variable response to existing ERTs.
  • Emerging pipeline therapies, including gene therapies and enhanced GAA replacement approaches, are expected to reshape the future treatment paradigm.

Market Overview

  • The Germany Pompe Disease market is projected to grow from USD 74 million in 2025 to USD 185 million by 2035, indicating substantial market expansion over the forecast period.
  • Market growth is driven by:
  • Increasing diagnosis and treatment rates among late-onset Pompe Disease patients
  • Rising adoption of advanced and premium-priced enzyme replacement therapies
  • Improved patient survival and long-term disease management
  • Future market expansion will largely depend on innovations that improve long-term functional outcomes, reduce treatment burden, and address progressive muscle deterioration.

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Genzyme, a Sanofi Company
  • Shionogi
  • AskBio Inc.
  • Amicus Therapeutics
  • GeneCradle Inc.
  • Astellas Gene Therapies

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)